| access_basis,doi_or_url,filename_stored_or_displayed,incorporation_decision,module_or_table,paper_title,rationale,short_title,source_category,source_id,source_pdf_size_mb,value_origin,year | |
| open_access_or_freely_downloadable_pdf_available_to_developer,10.1089/nat.2024.0090,no,row_level_module_added,galnac_sirna_risc_offtarget_mechanism.csv,Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates,High-priority mechanistic source for AGO2/TNRC6-mediated GalNAc-siRNA off-target hepatotoxicity.,agarwal-galnac-sirna-offtarget-2025,core,AGARWAL_GALNAC_SIRNA_OFFTARGET_2025,1.64399,source_inventory_metadata,2025 | |
| open_access_or_freely_downloadable_pdf_available_to_developer,10.1093/nar/gkad067,no,row_level_reference_module_added,approved_oligo_chemistry_landscape.csv,"Chemistry, Structure and Function of Approved Oligonucleotide Therapeutics",Standardizes approved-oligo chemistry and delivery terminology.,egli-manoharan-approved-oligo-chemistry-2023,core_reference,EGLI_MANOHARAN_APPROVED_OLIGO_CHEMISTRY_2023,10.07143,source_inventory_metadata,2023 | |
| open_access_or_freely_downloadable_pdf_available_to_developer,10.1016/j.jhep.2024.12.046,no,row_level_module_added,pnpla3_azd2693_precision_mash.csv,"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials",Original clinical/preclinical PNPLA3 ASO target-engagement source.,armisen-azd2693-pnpla3-aso-mash-2025,core,ARMISEN_AZD2693_PNPLA3_ASO_MASH_2025,1.27878,source_inventory_metadata,2025 | |
| open_access_or_freely_downloadable_pdf_available_to_developer,10.1016/j.cmet.2018.03.004,no,platform_module_added,rna_targeted_therapeutics_platform.csv,RNA-Targeted Therapeutics,"Broad platform logic for ASO versus siRNA structure, chemistry, distribution, and mechanism.",crooke-rna-targeted-therapeutics-2018,supporting,CROOKE_RNA_TARGETED_THERAPEUTICS_2018,2.35325,source_inventory_metadata,2018 | |
| open_access_or_freely_downloadable_pdf_available_to_developer,10.1038/s42003-026-09650-7,no,methods_module_added,nat_model_selection_evidence.csv,Model Selection in Preclinical Nucleic Acid Therapeutics Research,Adds model-selection and sequence-alignment rigor for NAT development.,oliver-hill-model-selection-nat-2026,supporting_methods,OLIVER_HILL_MODEL_SELECTION_NAT_2026,2.25666,source_inventory_metadata,2026 | |
| open_access_or_freely_downloadable_pdf_available_to_developer,10.3390/ph19020244,no,landscape_module_added,fda_tides_2025_oligo_landscape.csv,2025 FDA TIDES (Peptides and Oligonucleotides) Harvest,Current FDA approval landscape and GalNAc hepatocyte-targeting trend.,alshaer-fda-tides-harvest-2025,supporting_landscape,ALSHAER_FDA_TIDES_HARVEST_2025,0.84536,source_inventory_metadata,2026 | |
| open_access_or_freely_downloadable_pdf_available_to_developer,10.1056/NEJMoa1712191,no,row_level_module_added,hsd17b13_genetics_aso_translation.csv,A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease,Foundational human-genetics target rationale for HSD17B13 silencing.,abulhusn-hsd17b13-protective-variant-2018,core,ABULHUSN_HSD17B13_PROTECTIVE_VARIANT_2018,0.56958,source_inventory_metadata,2018 | |
| open_access_or_freely_downloadable_pdf_available_to_developer,10.1016/j.jlr.2024.100514,no,row_level_module_added,hsd17b13_genetics_aso_translation.csv,Evaluation of antisense oligonucleotide therapy targeting Hsd17b13 in a fibrosis mice model,"Preclinical Hsd17b13 ASO knockdown, steatosis response, and fibrosis limitation evidence.",ma-hsd17b13-aso-fibrosis-mouse-2024,core,MA_HSD17B13_ASO_FIBROSIS_MOUSE_2024,4.26722,source_inventory_metadata,2024 | |